Table 3.
Combined Active and Passive Immunotherapies for Glioma Patients
| Center/Investigator | Therapy/Protocol | Phase/Enrollment Number | ND, P, R* | WHO Grade** | Clinicaltrials.gov identifier | References |
|---|---|---|---|---|---|---|
| Duke Univ, Durham, NC/D Mitchell | CMV-DCs ± CMV-ALT + TMZ ± Skin site preparation (unpulsed DC or tetanus toxoid) | I/II - 16 | ND | IV | NCT00639639 | Mitchell et al [16,77] |
| Duke Univ, Durham, NC/D Mitchell | CMV-ALT ± CMV-DCs + RT + TMZ (intratumoral CMV-DC upon recurrence) | I - 12 | ND | IV | NCT00693095 | Mitchell et al [16,77] |
| Duke Univ, Durham, NC/D Mitchell | CMV-ALT ± CMV-DC or CMV-DC ± CCR7-DC | I/II - 20 | ND | IV | NCT00627224 | Mitchell et al [16,77] |
| St. Lukes Hosp, Kansas City, MO/M Salacz | Autologous Tumor Cells + GM-CSF → iv Activated T Cells + IL-2 (TVAX) | I/II - 10 | R | III or IV | NCT01081223 | Wood et al [39] |
* ND, Newly Diagnosed; P, Persistent; R, Recurrent
** WHO Grade III: AA, AODG; Grade IV: GBM